Rockley Photonics announces Medtronic partnership in another step towards bringing its non-invasive blood pressure wearable to market
Rockley Photonics Holdings Limited has announced an agreement with Medtronic, a medical device company primarily operating in the US. In a press release, Rockley confirmed that it and Medtronic would collaborate to integrate its Bioptx biomarker sensing platform within the latter's various healthcare solutions. In a statement, Dr. Andrew Rickman, Chairman and CEO of Rockley, said:
This partnership combines Medtronic's exceptional strength in providing in-patient care with Rockley's expertise in wearable, remote monitoring. I believe that this collaboration will bring to life our vision of giving people better insights into their health and well-being. We are excited about the potential for this partnership to herald the next generation of wearable devices and deliver a complete lifecycle of patient care.
As we discussed in January, Rockley's sensing platform has been demoed in a wrist-based device that can measure blood pressure and blood sugar levels non-invasively. While Rockley's sensing platform passed initial human trials, it has not conducted the clinical trials needed to receive FDA approval. According to Gadgets & Wearables, Rockley and Medtronic's partnership will help scale Bioptx manufacturing before its public release.
Currently, Rockley and Medtronic hope to reach 'volume production' by Q4 2022. If the pair achieve their aim, we should see Rockley's sensing platform hit the shelves sometime next year, possibly even in some smartwatches. You can read more about how the Bioptx biomarker sensing platform works on Rockley's website.